AstraZeneca Third Quarter 2026 Earnings Preview
AstraZeneca is scheduled to report its third-quarter 2026 financial results, with analysts projecting revenue of $15.99 billion and a net profit of $3.2 billion.
Stocks · News reference
AstraZeneca Therapies Impacted by Indian Trade Margin Rationalization
AstraZeneca's lung cancer therapies Osimertinib and Selumetinib were identified in the context of the Indian National Pharmaceutical Pricing Authority's trade margin rationalization exercise.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Participates as Platinum Sponsor for LUNGevity Foundation's 'Every Breath Forward' Initiative
AstraZeneca is serving as a Platinum Sponsor for the LUNGevity Foundation's 'Every Breath Forward' initiative, which aims to honor lives and support the lung cancer community.
Citi Maintains Buy Rating on AstraZeneca
Citi analyst Graham Parry has reaffirmed a buy rating for AstraZeneca, reflecting continued confidence in the company's outlook.